Taier Pharmaceutical Co., Ltd., also known as Taier Group, is the founder of Changsha National Bio-industrial Base, the largest bio-pharmaceutical industrial base in China. It is also the first batch of GMP pharmaceutical enterprises and the first batch of GMP nutrition and health care products enterprises in Chinese mainland.
In the field of pharmacy and technology, Teyr's sustained and controlled release preparation technology is in the leading position in the world, and it has completed major scientific and technological research achievements and market industrialization in China during the Ninth Five-Year Plan period. At the same time, he is the undertaker of major scientific and technological support projects during the Eleventh Five-Year Plan period and a special scientific research collaborator of the World Health Organization (WHO). Taier Pharmaceutical is also in a leading position in the field of natural nerve drugs in China, and its leading product is the market leader of natural nerve drugs in China.
In the field of nutrition and health care products: with the leading technology of sustained and controlled release preparations and the world-class scientific research platform of Tyle Bionutrition Laboratory in the United States, Tyle nutrition and health care products ranked first in the retail sales of pharmacies in East China (Jiangsu, Zhejiang and Shanghai) for many years (data source: retail market analysis report of the State Food and Drug Administration of the United States); Thiel is also a strategic brand partner of Luo Sailuo Group, a top European 100 enterprise in Asia.
Taier Pharmaceutical adheres to the corporate culture and core values of "leading technology, excellent quality" and "maximizing consumer value and interests", and is committed to providing consumers with the most valuable achievements and services.